Thymalin vs Thymosin Alpha-1: Which Thymus Peptide for Your Research Goal?
Thymalin vs Thymosin Alpha-1: defined peptide or thymus complex, mechanism and evidence compared. The decision guide for immune research.
Both peptides conceptually originate from thymus research and are studied for immune modulation and longevity. Yet they are fundamentally different: one is a precisely defined, clinically tested single peptide, the other a multi-substance complex from the thymus with a geroprotection tradition. This guide helps with the selection and frames the evidence honestly.
For the depth of studies per substance, see the reference pages on Thymalin and Thymosin Alpha-1. Here the focus is on the decision between the two.
TL;DR: The Quick Decision
Thymosin Alpha-1: a defined 28-amino-acid peptide with an independently characterized mechanism and Western RCT data on immune modulation. Thymalin: a thymus polypeptide complex (not a single peptide) with immune-restoration and geroprotection positioning, but a markedly weaker, unreplicated body of evidence. Honestly: on evidence quality, Thymosin Alpha-1 is clearly ahead. The dramatic longevity figures for Thymalin come from a single, non-blinded cohort.
For research purposes only
This text frames research peptides. It is not medical advice, not a recommendation for use in humans, and does not replace consultation with a physician. The study doses mentioned are the doses used in the literature, not a dosing recommendation.
Quick selection by research goal
Defined, clinically studied immune peptide
The two options in detail
Thymosin Alpha-1: the defined, clinically tested peptide
Thymosin Alpha-1 (Tα1, Thymalfasin, brand name Zadaxin) is a precisely defined, synthetic 28-amino-acid peptide with an acetylated N-terminus, identical to the N-terminal fragment of the core protein Prothymosin alpha. The acetylation is required for full activity.
Mechanistically, in contrast to many thymus preparations, it is independently characterized in the Western literature: Tα1 activates dendritic cells via Toll-like receptor 9 (TLR9), drives a Th1-directed T-cell response, and through the induction of indoleamine 2,3-dioxygenase (IDO) simultaneously balances inflammation and tolerance [PMID 16804115].
Regulatory status (precise): marketed as Zadaxin/Thymalfasin in roughly 35 countries (among others for chronic hepatitis B and C as well as an immune adjuvant), but not approved by the FDA (only orphan-drug designations).
Clinical evidence (study doses, not a dosing recommendation):
- Chronic hepatitis B, Phase III RCT, double-blind, placebo-controlled: 1.6 mg subcutaneously twice per week over 6 months; higher sustained virological response than placebo, with a characteristically delayed response after the end of therapy [PMID 10607256].
- Severe sepsis (ETASS RCT): Tα1 arm with lower 28-day mortality and better immune recovery, but the difference did not reach conventional significance, so a trend, not proof [PMID 23327199].
- Metastatic melanoma, immune adjuvant, Phase II RCT: median survival 9.4 vs 6.6 months (P = .08), without additional toxicity [PMID 20194853].
- COVID-19 lymphopenia, retrospective (not an RCT): associated with reduced mortality and recovery of exhausted T cells [PMID 32442287].
Across the controlled studies, Tα1 was consistently described as well tolerated, without added toxicity even in combination with chemotherapy.
Synthetic 28-amino-acid immunomodulatory peptide. Approved as Zadaxin in 35+ countries for chronic hepatitis B and C. Studied in 30+ trials across 11,000+ subjects for immune modulation via TLR2/9 dendritic cell signaling.
Thymalin: the thymus polypeptide complex
Thymalin is not a single peptide, but a low-molecular-weight polypeptide fraction from calf thymus, a standardized mixture of several short peptides (roughly 1 to 10 kDa). Individual active fractions were later isolated from it and synthesized separately.
A thymus-hormone-like immune modulation is described: restoration of the number and ratio of T and B lymphocytes and their subpopulations, increased functional activity and phagocytosis [PMID 34476247].
The best-known geroprotection work is a long-term observation of 266 elderly individuals over 6 to 8 years, in which Thymalin (partly combined with the pineal peptide Epithalamin) was associated with markedly reduced mortality [PMID 14523363].
Important framing of the Thymalin evidence
The geroprotection study was an open, non-blinded cohort observation, not a randomized, double-blind, placebo-controlled trial. It combined Thymalin with Epithalamin, so the isolated effect of Thymalin is confounded. The entire Thymalin evidence base comes predominantly from a single research group and is largely Russian-language, without independent Western replication. The claim "extends lifespan" is therefore not established in the sense of modern evidence. The primary source also names no concrete mg dose.
Thymus-derived immune peptide developed by Prof. Khavinson. Restores T-cell function and thymic activity that naturally decline with age. Over 40 years of clinical use in Russia for immune support and anti-aging research.
Direct comparison at a glance
| Property | Thymosin Alpha-1 | Thymalin |
|---|---|---|
| Chemical identity | Defined 28-amino-acid peptide (sequenced) | Polypeptide complex from thymus (mixture) |
| Mechanism evidence | Independently characterized: TLR9, Th1, IDO/Treg [16804115] | Lymphocyte restoration, mostly described by the originating group [34476247] |
| Best evidence | Western RCTs (HepB, sepsis, melanoma) [10607256, 23327199, 20194853] | Single group, open geroprotection cohort [14523363] |
| Regulatory status | Zadaxin in ca. 35 countries; not FDA-approved | Clinical use in Russia/Eastern Europe; no Western approval |
| Positioning | Defined immune-modulation peptide | Thymus complex, geroprotection tradition |
| Evidence ranking | Stronger, reproducible, RCT-backed | Weaker, real but unreplicated |
Honest evidence assessment
On evidence quality, Thymosin Alpha-1 clearly leads Thymalin. Marketing often inverts this by putting Thymalin's dramatic mortality figures up front. These come from a single, non-blinded cohort that additionally gave a second peptide, and were never independently replicated. Tα1 acts rather moderately in any single study (several studies narrowly missed significance), but it is multinational, randomized, blinded, and mechanistically grounded.
Which peptide fits which goal?
You want a defined, clinically studied immune peptide
Thymosin Alpha-1. A sequenced single peptide with an independently characterized mechanism and Western RCT data on immune modulation [PMID 16804115, 10607256].
You research the thymus-complex and geroprotection tradition
Thymalin. The polypeptide complex with broad immune-restoration and longevity positioning, with the awareness that it is a mixture and that the longevity evidence comes from a single, non-blinded source.
Frequently asked questions
The substances described here are research peptides. This article serves solely for the dissemination of knowledge, is not medical advice, and is not to be understood as a recommendation for use in humans.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.